The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. Disclaimer. About Sandoz.

Biosimilars 52

Biosimilars Clinical Development Production Government 52

Drug Discovery World

JULY 21, 2023

Madrigal Pharmaceuticals has submitted an application for resmetirom, a drug for nonalcoholic steatohepatitis (NASH) with liver fibrosis, to the US Food and Drug Administration (FDA) and has requested a priority review.

FDA 130

FDA Drugs Clinical Development Pharmaceuticals 130

Drug Discovery World

JANUARY 16, 2024

The company was initially founded as partnership between three research organisations, Cambridge University, Imperial College London and University College London, and three pharmaceutical companies, AstraZeneca, GSK and J&J. “We

Pharmaceutical Companies 130

Pharmaceutical Companies Clinical Development Pharmaceuticals Disease 130

Drug Discovery World

JANUARY 5, 2023

CANbridge Pharmaceuticals has exercised its option to secure the exclusive global rights to develop, manufacture and commercialise a novel gene therapy to treat spinal muscular atrophy (SMA) from UMass Chan Medical School. .

Therapies 130

Therapies Medical Schools Clinical Development Pharmaceuticals 130

Drug Discovery World

AUGUST 4, 2023

“Since 2019, we have been following with interest the development of BWC0977 as a potential treatment for drug-resistant infections caused by the most harmful and deadly bacteria on the WHO priority pathogens list,” said Dr Manica Balasegaram, GARDP’s Executive Director. “We

Clinical Development 130

Clinical Development Hospitals Research Pharmaceuticals 130

Drug Discovery World

FEBRUARY 27, 2023

Under a new agreement, Destiny Pharma and Sebela Pharmaceuticals will co-develop NTCD-M3, Destiny’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence.

Clinical Trials 130

Clinical Trials Licensing Licensing Drugs 130

Drug Discovery World

JUNE 21, 2023

Citius Pharmaceuticals has revealed positive results from its Phase IIb Study of Halo-Lido (CITI-002) for the treatment of haemorrhoids. Following the 21 st Century Cures Act, higher emphasis is placed on using Patient Reported Outcome (PRO) instruments in clinical trials.

Trials 130

Trials Treatment Clinical Trials Clinical Development 130

Drug Discovery World

JANUARY 25, 2024

Our team is dedicated to advancing this therapy through clinical development as swiftly as possible.” ” In the development of the lead compound PTX-252, Pleco collaborated with Belgian company Hyloris Pharmaceuticals. ” Worldwide the incidence of AML is estimated to be 350,000 cases per year (4.7

FDA 130

FDA Drugs Clinical Trials Clinical Development 130

Drug Discovery World

JANUARY 6, 2023

Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA Pharmaceuticals’ PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer. . It contains multiple long peptides spanning the most immunogenic regions of the PRAME protein. .

Trials 130

Trials Clinical Development Pharmaceuticals Therapies 130

Conversations in Drug Development Trends

DECEMBER 7, 2023

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

The Pharma Data

MARCH 13, 2022

NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Pfizer Inc.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Biosimilars Disease 52

Drug Discovery World

DECEMBER 13, 2023

A Phase II clinical trial of FR104/VEL-101 in patients undergoing kidney transplantation is under preparation by OSE’s partner Veloxis Pharmaceuticals. In the FIRsT Phase I/II clinical trial, seven patients completed one-year treatment with FR104/VEL-101 and one is ongoing (Month 4).

Clinical Trials 130

Clinical Trials Hospitals Trials Clinical Development 130

The Pharma Data

SEPTEMBER 29, 2021

The new FIND-CKD study extends our clinical research for finerenone to a non-diabetic population where the unmet need is high for brand spanking new treatments to delay disease progression.”.

Clinical Development 52

Clinical Development Disease Clinical Trials Trials 52

Drug Discovery World

JANUARY 10, 2024

The acquisition includes Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for asthma, with potential for additional indications.

Pharmacokinetics 130

Pharmacokinetics Licensing Licensing Clinical Development 130

The Pharma Data

MAY 2, 2021

Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. Disclaimer. About Sandoz.

Biosimilars 40

Biosimilars Clinical Development Production Government 40

The Pharma Data

OCTOBER 21, 2020

and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme.

Clinical Development 52

Clinical Development Therapies Clinical Trials FDA Approval 52

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Pharmaceutical Companies 98

Pharmaceutical Companies Clinical Research Clinical Development Drug Development 98

Drug Discovery World

MARCH 16, 2023

The artificial intelligence solutions developed by Iktos are aimed to considerably speed up the drug discovery process, while increasing the probability of success of drug candidates reaching clinical development.

Drugs 130

Drugs Clinical Development Pharmaceuticals Research 130

The Pharma Data

DECEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain. executive vice president of research and development. “The executive vice president of research and development. “We About Lexicon Pharmaceuticals.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

The Pharma Data

FEBRUARY 24, 2022

There is a high unmet need for treatments that can reduce the extensive burden associated with the progression of kidney disease and the connected risk of cardiovascular events,” said Dr. Michael Devoy, Chief Medical Officer and Head of Medical Affairs and Pharmacovigilance at Bayer’s Pharmaceuticals Division. “We

Clinical Development 52

Clinical Development Disease Therapies Treatment 52

Drug Discovery World

FEBRUARY 16, 2023

The two new senior researchers will also work with colleagues at Imperial College London’s School of Public Health in our joint Cancer Epidemiology and Prevention Research Unit (CEPRU). Steve Yemm, Optibrium: Optibrium has appointed Steve Yemm as Chief Commercial Officer (CCO).

Small Molecule 130

Small Molecule Pharmaceuticals Clinical Development Science 130

The Pharma Data

JANUARY 21, 2021

–( BUSINESS WIRE )– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. 22, 2021 12:00 UTC.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

Sygnature Discovery

JANUARY 26, 2024

Leveraging years of experience, we efficiently advance your compounds through preclinical studies and reduce risks as you move into clinical development. Our talented team of scientists can assist you in crafting robust pre-clinical development strategies.

Process Chemistry 52

Process Chemistry Pharmacokinetics Clinical Development Laboratories 52

The Pharma Data

OCTOBER 15, 2020

. ASLAN appoints neurologist Professor Gavin Giovannoni as a scientific advisorto establish clinical development strategy in multiple sclerosis. Following an internal strategic review and noting changes in the AML treatment landscape, ASLAN will be focusing the future development of ASLAN003 in autoimmune disease.

Pharmaceuticals 40

Pharmaceuticals Cell Based Assays Clinical Development Treatment 40

Drug Discovery World

MAY 25, 2023

Broughton: new inhalation testing service The service is designed to help pharmaceutical companies bring orally inhaled and nasal drug products (OINDPs) to market efficiently. The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos.

Production 130

Production DNA Assay Development Drugs 130

Drug Discovery World

MAY 6, 2024

Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany. Members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) spent €41.5

Drugs 148

Drugs Science Molecular Biology Clinical Trials 148

Drug Discovery World

MAY 3, 2023

Vicore Pharma, a Swedish clinical-stage pharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists (ATRAGs), has dosed its first patient with C21 in a clinical study of endothelial dysfunction. Vicore Pharma states that results from the trial are expected in Q4, 2023.

FDA Approval 130

FDA Approval Trials Pharmaceutical Companies Disease 130

Drug Discovery World

FEBRUARY 12, 2024

In 2024, we can expect another wave of innovative new drugs to be developed using the technology, given that the AI-fuelled small molecule discovery pipeline is growing by almost 40% annually.”

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

The Pharma Data

DECEMBER 1, 2020

01, 2020 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. About Allena Pharmaceuticals Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Clinical Development 52

Drug Discovery World

NOVEMBER 22, 2022

Cancer Research UK’s innovation engine, Cancer Research Horizons, and Newcastle University, have agreed an extension of their strategic drug discovery alliance with Astex Pharmaceuticals. .

Drugs 130

Drugs Engineering Clinical Development Research 130

The Pharma Data

OCTOBER 26, 2020

This additional extension of the collaboration will allow us to choose the best CDX antibody for pre-clinical and clinical development.” Enquiries: Hemogenyx Pharmaceuticals plc. About Hemogenyx Pharmaceuticals plc. . [link].

Pharmaceuticals 40

Pharmaceuticals Engineering Regulations Pharmaceutical Companies 40

Drug Discovery World

JUNE 27, 2023

It will be headquartered at the Monash Institute of Pharmaceutical Sciences (MIPS). The Drug Discovery Initiative at the University of Sydney is thrilled to collaborate with the Monash Institute of Pharmaceutical Sciences and WEHI to create this much needed national framework. MedChem Australia will fill this gap.

Medical Chemistry 130

Medical Chemistry Drugs Pharmacokinetics Science 130

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

Conversations in Drug Development Trends

APRIL 15, 2024

Worldwide Clinical Trials recently conducted a comprehensive research study, where we included 140 key industry-decision makers from biotech and pharmaceutical companies of all sizes. Discover how Worldwide is positioned to meet your needs with agility, expertise, and a truly personalized approach.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Pharmaceutical Companies 52

The Pharma Data

JANUARY 10, 2021

Dr. Ken Kobayashi, CMO, ASLAN Pharmaceuticals, commented: “The emerging safety profile of ASLAN004 has allowed us to move directly into the expansion cohort at the highest dose, 600mg weekly, based on blinded safety data, accelerating the completion of the study. SINGAPORE, Jan. Media and IR contacts. Forward looking statements.

Clinical Trials 52

Clinical Trials Pharmaceuticals Trials Treatment 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. Dr. Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” About Aridis Pharmaceuticals, Inc. Aridis Pharmaceuticals, Inc. SAN JOSE, Calif. ,

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

Drug Discovery World

MARCH 25, 2024

“By welcoming Cardior as a part of Novo Nordisk, we will strengthen our pipeline of projects in cardiovascular disease where we already have ongoing programmes across all phases of clinical development,” said Martin Holst Lange, Executive Vice President for Development at Novo Nordisk. “We

Therapies 130

Therapies RNA Disease Trials 130